Psilocybin in end of life care: Implications for further research

Abstract

Get full access to this article

View all access options for this article.

References

Carhart-Harris

Bolstridge

Rucker

. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619–627.

Carhart-Harris

Erritzoe

Williams

. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138–214.

Griffiths

Johnson

Carducci

. (2016) Psilocybin produces substantial and sustained decrease in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30: 1181-1197.

Grob

Danforth

Chopra

. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78.

Lebedev

Lovden

Rosenthal

. (2015) Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36: 3137–3153.

Nichols

(2015) Psychedelics. Pharmacol Rev 68: 264–355.

Ross

Bossis

Guss

. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30: 1165-1180.

Select Committee on Intelligence (1977) Project MKULTRA. US Government Printing Office Washington, DC.